Skip to main content

Advertisement

Neurotransmetteurs cérébraux et contrôle du comportement sexuel masculin

Resume

Des progrès importants, quoiqu'encore parcellaires, ont été accomplis dans la compréhension du rôle que jouent les neurotransmetteurs mono-aminergiques et peptidergiques dans le contrôle du comportement sexuel (CS) animal, et à un moindre degré humain. Parmi les mono-amines, la dopamine stimule tous les aspects du CS chez l'animal et au moins l'érection chez l'homme. La noradrénaline semble impliquée dans un tonus adrénergique central inhibiteur s'exprimant par l'intermédiaire des récepteurs alpha 2. La sérotonine exerce des effects inhibiteurs ou stimulants selon le type de récepteur concerné, et peut particulièrement induire chez le rat un comportement de type éjaculation prématurée, alors que les inhibiteurs de sa recapture améliorent la dysfonction correspondante chez l'homme. Parmi les neuropeptides, les substances opioïdes et particulièrement la bétaendorphine inhibent tous les aspects du CS, et sont probablement des intermédiaires des effects du stress sur la sexualité. De nombreux autres peptides sont capables d'affecter le CS dans certains protocoles expérimentaux, mais leur implication physiologique n'est pas connue. Ceux dont les effects sont les plus spectaculaires sont la somatostatine, l'ocytocine, et le neuropeptide Y. Certaines données permettent d'espérer qu'on puisse tirer à moyen terme un bénéfice thérapeutique de manipulations de la dopamine, la noradrénaline, la sérotonine, ou des opioïdes centraux dans les dysfonctions sexuelles de l'homme. Ces progrès sont pour l'instant limités par l'importance des effects indésirables extrasexuels, eux-mêmes fonction de la spécificité insuffisante des agonistes ou antagonistes utilisés.

References

  1. 1.

    ABBOTT D.H., HOLMAN S.D., BERMAN M., NEFF D.A., GOY R.W.: Effects of opiate antagonists on hormones and behavior of male and female rhesus monkeys. Arch. Sex. Behav., 1984, 13: 1–26.

  2. 2.

    ALBO M., SWERS W.D.: Oral trazodone as initial therapy for the management of impotence; J. Urol., 1993, 149: 344A.

  3. 3.

    ASSALIAN P.: Clomipramine in the treatment of premature ejaculation; J. Sex. Res., 1988, 24: 213–215.

  4. 4.

    BANCROFT J.: Effects of alpha 2 antagonists on male erectile response; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 215–221.

  5. 5.

    BAUM M.J.: Reassessing the role of medical preoptic area/anterior hypothalamic neurons in appetitive aspects of masculine sexual behavior; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 133–139.

  6. 6.

    BENKERT O.: Pharmacological experiments to stimulate human sexual behavior; In: Psychopharmacology of sexual disorders and drug abuse. T.A. Ban, North Holland, Amsterdam, 1973, 489–495.

  7. 7.

    BENKERT O., CROMBACH G., KOCKOTT G.: Effect of L-dopa on sexually impotent patients; Psychopharmacologia, 1972, 23: 91–95.

  8. 8.

    BENKERT O., JORDAN R., DHALEN H.G., SCHNEIDER H.P.G., GAMMEL G.: Sexual impotence: a double-blind study of LHRH-nasal spray versus placebo. In: Neuropsychobiology. 1975, 1: 203–210.

  9. 9.

    BERTOLINI A., FRATTA W., GESSA G.L., MONTALDO S., SERRA G.: Penile erection during morphine withdrawal: possible role of ACTH-MSH peptides. In: Central and peripheral endorphins. Basic and clinical aspects. Raven Press, New York, 1979, 365–388.

  10. 10.

    BOHUS B.: The influence of pituitary neuropeptides on sexual behavior; In: Hormones et sexualité. H.P. Klotz ed. Expansion Scientifique Française, Paris, 1977, 235–246.

  11. 11.

    BRENNEMANN W., STITZ B., VAN AHLEN H., BRENSING A., KLINGMÜLLER D.: Treatment of idiopathic erectile dysfunction in men with the opiate antagonist naltrexone-A double-blind study; J Andrology, 1993, 14: 407–410.

  12. 12.

    BUVAT J.: Hormones et comportement sexuel de l'homme: données physiologiques et physiopathologiques. Contr. Fertil. Sex. 1996, sous presse.

  13. 13.

    BUVAT J., BUVAT-HERBAUT M., LEMAIRE A., KORNOBIS C.: Perturbations sexuelles masculines d'origine médicamenteuse. In: Perturbations iatrogènes de la sexualité; J. Buvat et J. Hermabessière eds, Progrès en Andrologie I, Doin, Paris, 1987, 48–60.

  14. 14.

    BUVAT J., BUVAT-HERBAUT M., LEMAIRE A., MARCOLIN G.: Hormones, neurotransmetteurs centraux et comportement sexual de l'homme. In: Andrologie III, Arvis G. ed., Maloine, Paris, 1991: 1161–1189.

  15. 15.

    CARMICHAEL M.S., HUMBERT R., DIXEN J., PALMISANO G., GREENLEAF W., DAVIDSON J.M.: Plasma oxytocin increases in the human sexual response. J. Clin Endocrinol. Metab., 1987, 64: 27–31.

  16. 16.

    CLARK J.T.: Sexual arousal and performance are modulated by adrenergic-neuropeptide-steroid interactions; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica. Amsterdam, 1995, 6: 55–68.

  17. 17.

    CRENSHAW T.L., GOLDBERG J.P., STERN W.C.: Pharmacologic modification of psychosexual dysfunction; J. Sex. Marital Ther., 1987, 13: 239–253.

  18. 18.

    DAVIES T.F., GOMEZ-PAN A., WATSON M.J., MOUNT JOY C.Q., HANKER J.P., BESSER G.M. et al.: Reduced gonadotrophin response to releasing hormone after chronic administration to impotent men, Clin. Endocrinol., Oxford, 1977, 6: 213–218.

  19. 19.

    DE LA FUENTE R.B., KROPMAN R.F., MEINHARDT W., LYCKLAMA à NIJEHOLT A.A.B., ZWARTENDIJK J.: Trazodon versus placebo for impotence treatment. First congress of the european society for impotence research (ESIR), Porto Carras, September 1995. Int. J. Impotence Res. 1995, 7, Suppt 1: 115.

  20. 20.

    DEMYTTENAERE K., VANDERSCHUEREN D.: Selective serotonin reuptake inhibitors and sexual function; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 327–339.

  21. 21.

    DORNAN W.A., MALSBURY C.W.: Neuropeptides and male sexual behavior. Neurosci. Biobehav. Rev. 1989, 13: 1–15.

  22. 22.

    EHRENSING R.H., KASTIN A.J., SCHALLY A.V.: Behavioral and hormonal effects of prolonged high doses of LHRH in male impotency. Peptides, 1981, 2: 115–121.

  23. 23.

    EVANS I.M., DISTILLER L.A.: Effects of luteinizing hormone releasing hormones on sexual arousal in normal men. Arch. Sex. Behav., 1979, 8: 385–395.

  24. 24.

    EVERITT B.J.: Neuroendocrine mechanisms underlying appetitive and consummatory elements of masculine sexual behaviour; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 15–31.

  25. 25.

    EVERITT B.J., BANCROFT J.: Of rats and men: the comparative approach to male sexuality. In: annual review of sex research, J. Bancroft ed., 1991, II, 77–117.

  26. 26.

    EVERITT B.J., HANSEN S.: Catecholamines and hypothalamic mechanisms; In: Psychopharmacology and Sexual Disorders. D. Wheatley ed. Oxford University Press, 1983, 3–14.

  27. 27.

    FABBRI A., JANNINI E.A., GNESSI L., MORETTI C., ULISSE S., FRANZESE A., et al.: Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology, 1989, 14: 103–111.

  28. 28.

    FRAJESE G., LAZZARI R., MAGNANI A., MORETTI C., SFORZA V., NEROZZI D.: Neurotransmitter, opioïdergic system, steroid hormone interaction and involvement in the replacement therapy of sexual disorders, J. Steroid Biochem. Molec. Biol. 1990, 37: 411–419.

  29. 29.

    GAY R.W., DAVIS G.A., BAUM S.: Influences of a specific Dopamine-2 Agonist (L4163502) on erection and sexual performance in primates; Abstracts of the 15th meeting of the international academy for sex research, Princeton, New Jersey, 1989, 12.

  30. 30.

    GIULIANO F., RAMPIN O., BENOIT G., JARDIN A.: Neural control of penile erection; Urologic clinics of North America, 1995, 22: 747–766.

  31. 31.

    GLICK B.B., BAUGHMAN W.L., JENSEN J.N., PHOENIX C.H.: Endogenous opiate systems and primate reproduction: inability of naloxone to induce sexual activity in rhesus males. Arch. Sex. Behav., 1982, 11: 267–276.

  32. 32.

    GOLDSTEIN J.A.: Erectile function and naltrexone. Ann. Intern. Med., 1986, 105: 799–803.

  33. 33.

    GRUGNI G., CARANI C., MAESTRONI G., GUZZALONI G., ARDIZZI A., LISSONI P. et al.: Melatonin Levels in Psychogenic Impotence; Horm metab. Res., 1994, 26: 440–441.

  34. 34.

    HAENSEL S.M., ROWLAND D.L., SLOB A.K.: Serotoninergic drugs and masculine sexual behavior in laboratory rats and men; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 235–247.

  35. 35.

    HEATON J.P.W., MORALES A., ADAMS M.A.: Recovery of erectile function by the oral administration of apomorphine; Urology, 1995, 45: 300–306.

  36. 36.

    HERBERT J.: Neuropeptides, stress and sexuality: Towards a new psychopharmacology; In The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 77–92.

  37. 37.

    HOFFMAN B.B., LEFKOWITZ R.J.: Alpha-adrenergic receptors subtypes; N. Engl. J. Med., 1980, 302: 1390–1396.

  38. 38.

    HUGHES A.M., EVERITT B.J., HERBERT J.: The effects of simultaneous or separate infusions of some pro-opiomelanocortin derived peptides (beta-endorphin, melanocyte stimulating hormone, and corticotropin-like intermediate polypeptide) and their acetylated derivatives upon sexual and ingestive behavior of male rats. Neuroscience, 1989, 27: 689–711.

  39. 39.

    KENDRICK K.M., DIXSON A.F.: Luteinizing Hormone Releasing Hormone enhances proceptivity in a primate. Neuroendocrinology, 1985, 41: 449–453.

  40. 40.

    KIM S.C., OH M.M.: Norepinephrine involvement in response to intracorporeal injection of papaverine in psychogenic impotence; J. Urol., 1992, 147: 1530–1532.

  41. 41.

    KIMURA Y., KISAKI N., SAKURADA S., TADANO T.: On the brain monoaminergic systems relating to ejaculation. I. Brain dopamine and ejaculation. Andrologia, 1976, 8: 313–320.

  42. 42.

    KURT U., OXCARDEZ H., ALTUG U.: The efficacy of antiserotoninergic agents in the treatment of erectile dysfunction; J. Urol., 1992, 152: 407–409.

  43. 43.

    LAL S., ACKMAN D., THAVUNDAYIL J.X., KILY M.E., ETIENNE P.: Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects; Progress Neuro-Psychopharmacol. Biol. Psychiatry, 1984, 8: 695–699.

  44. 44.

    LARSSON K., AHLENIUS S.: Masculine sexual behavior and brain monoamines. In: Psychopharmacology of sexual disorders. Biological Psychiatry — New prospects no 4, M. Segal ed., J. Libbey, Londres, 1985, 15–32.

  45. 45.

    MAS M., FUMERO B., PEREZ-RODRIGUEZ I., GONZALES-MORA J.L.: The neurochemistry of sexual satiety. An experimental model of inhibited desire; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 115–126.

  46. 46.

    MORALES A., CONDRA M., OWEN J.A., SURRIDGE D.H., FENEMORE J., HARRIS C.: Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J. Urol., 1987, 137: 1168–1172.

  47. 47.

    MURPHY M.R.: Endogenous opiates and the mechanism of male sexual behavior. In: Psychopharmacology of sexual disorders. Biological Psychiatry — New prospects no4, M. Segal ed., J. Libbey, Londres, 1985, 51–62.

  48. 48.

    OGAWA S., KUDO S., KITSUNAI Y., FUKUCHI S.: Increase in oxytocin secretion at ejaculation in male. Clin. Endocrinol., Oxford, 1980, 13: 95–98.

  49. 49.

    PARMEGGIANA P.L., MORRISON A.R.: Central regulation of autonomic function; AD Loewy et KM Spyer eds, Oxford University Press, New York 1990.

  50. 50.

    PFAUS J.G., EVERITT B.J.: The psychopharmacology of sexual behavior; In: Psychopharmacology, the fourth generation of progress, F.E. Bloom et D.J. Kupfer eds, Raven press, New York, 1994, 743–758.

  51. 51.

    POMERANTZ S.M.: Monoamine influences on male sexual behaviour of non human primates; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 201–211.

  52. 52.

    POWER-SMITH P.: Beneficial sexual side-effects from fluoxetine; Br. J. Psychiatry, 1994, 164: 249–250.

  53. 53.

    PRZEWLOCKI R., PRZEWLOCKI B., LASON W.: Stress and beta-endorphin secretions; In: Neurobiology of opioïds. O.F.X. Almeida et T.S. Shippenberg eds, Springer-Verlag, Berlin, 1991: 229–243.

  54. 54.

    PSIET J.S., WON LEE S.: The neural mechanism of apomorphin induced erection: an experimental study by comparison with electrostimulation induced erection in the rat model; J. Urol., 1994, 152: 2125–2128.

  55. 55.

    REID K., SURRIDGE D.H.C., MORALES A., CONDRA M., HARRIS C., OWEN J. et al.: Double-blind trial of yohimbine in the treatment of psychogenic impotence; Lancet, 1987, ii, 421–423.

  56. 56.

    RILEY A.J.: Oxytocin and coitus. Sex. Marit. Ther., 1988, 3: 29–36.

  57. 57.

    RILEY A.J.: Alpha adrenoceptors and human sexual function; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 307–322.

  58. 58.

    RILEY A.J., GOODMAN R.E., KELLER J.M., ORR R.: Double-blind trial of yohimbine hydrochloride in the treatment of erection inadequacy; Sex. Marit. Therapy., 1989, 4: 17–26.

  59. 59.

    ROSEN R.C., ASHTON A.K.: Prosexual Drugs: Empirical Status fo the “New Aphrodisiacs”; Arch. Sex. Behav., 1993, 22: 521–543.

  60. 60.

    SAENZ DE TEJADA I., WARE J.C., BLANCO R.: Pathophysiology of prolonged penile erection associated with trazodone use; J. Urol, 1991, 145: 60–66.

  61. 61.

    SONDA L.P., MAZO R., CHANCELLOR M.B.: The role of yohimbine for the treatment of erectile impotence; J. Sex. Marital Ther., 1990, 16: 15–22.

  62. 62.

    SEGRAVES R.T.: Dopamine agonists and their effect on the human penile erectile response; In: The pharmacology of sexual function and dysfunction. J. Bancroft ed. Excerpta medica, Amsterdam, 1995, 6: 225–229.

  63. 63.

    STRATTA P., MANCINI F., CUPILLARI M., ROSSI A., CASACCHIA M.: Fluoxetine in premature ejeculation; Human Psychopharmacology, 1993, 8: 61–64.

  64. 64.

    SUSSET J.G., TESSIER C.D., WINEZE J., BANSAL S., MALHOTRA C., SCHWACHA M.G.: Effect of yohimbine hydrochloride on erectile impotence: a double-blind study; J. Urol., 1989, 141: 1360–1363.

  65. 65.

    TENNENT G., BANCROFT J., CASS J.: The control of deviant sexual behavior by drugs: a double-blind controlled study of benperidol, chlorpromazine and placebo. Arch. Sex. Behav., 1974, 3: 261–271.

  66. 66.

    TINDAL R.J.S.: Stimuli that cause the release of oxytocin; In: Handbook of physiology, Endocrinology 4. Geiger ed., American Physiology Association, Washington DC, 1975.

  67. 67.

    WIEDEKING C., ZIEGLER M.G., LAKE C.R.: Plasma noradrenaline and dopamine beta-hydrosylase during human sexual activity; J. Psychiatr. Res., 1979, 15: 139–145.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Buvat, J. Neurotransmetteurs cérébraux et contrôle du comportement sexuel masculin. Androl. 6, 184–199 (1996). https://doi.org/10.1007/BF03034448

Download citation

Mots clés

  • Comportement sexuel
  • neurotransmetteurs
  • neuropeptides
  • dopamine
  • noradrénaline
  • serotonine
  • béta-endorphine
  • opioïdes
  • somatostatine
  • ocytocine
  • neuropeptide Y
  • CRH, ACTH
  • alphaMSH
  • LHRH
  • Angiotensine II
  • Substance P